60 Degrees Pharma Posts 65% Revenue Surge, Narrows Net Loss to $7.37M
60 Degrees Pharmaceuticals reported 2025 net product revenues of $1.005 million, up 65% from 2024, and a gross profit of $223.8 thousand while narrowing its net loss to $7.37 million from $7.96 million. Operating expenses fell to $8.4 million from $10.0 million and a $4.0 million ATM raise exhausted the company’s current shelf, setting the stage for an interim clinical data release as soon as late September.
1. Fiscal 2025 Financial Performance
60 Degrees Pharmaceuticals achieved net product revenues of $1.005 million in fiscal 2025, up 65% from $607.6 thousand in 2024, delivering a gross profit of $223.8 thousand. Operating expenses declined to $8.4 million from $10.0 million, driving a net loss of $7.37 million, or $11.73 per share, compared with $7.96 million, or $74.17 per share, in the prior year.
2. ATM Facility and Equity Position
In the twelve months through March 27, 2026, the company offered and sold $4.03 million in common shares via its at-the-market facility, exhausting its current baby shelf capacity. As of March 30, 2026, the company had 2,636,788 shares outstanding, with no remaining shelf capacity available.
3. Clinical Progress and Strategic Partnerships
The expanded access study for relapsing babesiosis achieved a 100% cure rate with tafenoquine-based treatment, prompting calls to update treatment guidelines. The company expects an interim analysis from its Phase 2 randomized hospital trial by late September if 2026 tick-season recruitment mirrors 2025, while partnerships with GoodRx and Runway Health extend ARAKODA® access through over 70,000 pharmacies and telehealth channels.